Antimitotic Inhibitors - 20/04/12
Corresponding author.Résumé |
Of the agents available in the treatment of both solid and hematologic cancers, microtubule-targeted agents are among the most widely used and exploiting other mechanisms involving the microtubule and its role in mitosis is an area of continued interest. This review will focus on novel microtubule-targeted agents, both recently approved (eg, ixabepilone and eribulin) and in later-stage clinical trials, and kinase inhibitors that aim to directly inhibit the mitotic spindle, such as the aurora kinase, pololike kinase, and kinsein-spindle protein inhibitors.
Le texte complet de cet article est disponible en PDF.Keywords : Microtubule-targeting agents, Microtubule resistance, Epothilones, Eribulin, Cabazitaxel, Aurora kinase inhibitors, PLK inhibitors, KSP inhibitors
Plan
Vol 26 - N° 3
P. 607-628 - juin 2012 Retour au numéro
Article précédent
- Tyrosine Kinase Inhibitors in Lung Cancer
- Anish Thomas, Arun Rajan, Giuseppe Giaccone
- The Antifolates
- Michele Visentin, Rongbao Zhao, I. David Goldman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?